Iambic Therapeutics, a San Diego drug discovery company, aims to raise about $150 million in its IPO, at a roughly $760 million valuation.
Why it matters: The offering comes at an inflection point for AI drug discovery, as investors seek tangible returns on the technology's promise of faster, better drug development.
